🩺 The trial will investigate the candidate in ovarian cancer and lung adenocarcinoma.
🎯 TUB-040 targets the highly overexpressed antigen NaPi2b.
🧪 Tubulis’ ADC linker technology has demonstrated effective and durable responses in preclinical models.
Introduction:
Munich-based biotech company Tubulis has announced that it has dosed the first patient in a Phase 1/2a trial for its antibody-drug conjugate (ADC) TUB-040. The trial will evaluate the safety and efficacy of TUB-040 as a monotherapy in patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory adenocarcinoma non-small cell lung cancer. TUB-040 targets NaPi2b, a highly overexpressed antigen in these types of cancer. It is Tubulis’ first candidate to enter clinical trials and uses the company’s proprietary linker technology with superior biophysical properties.
- Tubulis has dosed the first patient in a Phase 1/2a trial of its ADC TUB-040.
- TUB-040 is being investigated as a monotherapy in patients with ovarian cancer or lung adenocarcinoma.
- The ADC targets the highly overexpressed antigen NaPi2b.
- TUB-040 is the first candidate to enter clinical trials for Tubulis.
- The ADC uses Tubulis’ proprietary linker technology with better biophysical properties.
Conclusion:
Tubulis’ dosing of the first patient with its ADC TUB-040 in a Phase 1/2a trial represents an important milestone for the company. TUB-040 has shown promising preclinical results, demonstrating effective and durable responses in a range of models. The ADC targets a highly overexpressed antigen in ovarian cancer and lung adenocarcinoma, and the trial will investigate its safety and efficacy as a monotherapy. Tubulis’ proprietary linker technology, with its superior biophysical properties, sets TUB-040 apart from other ADCs in development.
